NCT02266355View on ClinicalTrials.gov

Role of Omalizumab in Reducing the Incidence of Oxaliplatin-induced Hypersensitivity Reaction

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

February 27, 2018

Study Completion Date

February 27, 2018

Conditions
Colon Cancer
Interventions
DRUG

Omalizumab

Omalizumab 300 mg SQ every 2 weeks

Trial Locations (1)

06519

Yale University, New Haven

All Listed Sponsors
lead

Yale University

OTHER

NCT02266355 - Role of Omalizumab in Reducing the Incidence of Oxaliplatin-induced Hypersensitivity Reaction | Biotech Hunter | Biotech Hunter